Texas Top Legal Officer Takes Legal Action Against Tylenol Makers Over Autism Spectrum Claims

Courtroom Proceedings
Ken Paxton, who supports former President Trump who is running for US Senate, accused pharmaceutical manufacturers of hiding safety concerns of Tylenol

Texas Attorney General Paxton is suing the manufacturers of Tylenol, alleging the companies concealed potential risks that the drug posed to children's cognitive development.

The court filing follows a month after Donald Trump publicized an unverified association between using Tylenol - alternatively called acetaminophen - throughout gestation and autism in children.

Paxton is filing suit against Johnson & Johnson, which once produced the drug, the sole analgesic suggested for expectant mothers, and the current manufacturer, which now manufacturers it.

In a official comment, he claimed they "deceived the public by making money from suffering and pushing pills without regard for the risks."

The manufacturer states there is no credible evidence tying acetaminophen to autism spectrum disorder.

"These manufacturers deceived for years, intentionally threatening millions to line their pockets," Paxton, a Republican, said.

The manufacturer stated officially that it was "very worried by the spread of false claims on the reliability of paracetamol and the likely effects that could have on the health of American women and children."

On its website, Kenvue also said it had "regularly reviewed the applicable studies and there is no credible data that shows a established connection between taking paracetamol and autism."

Organizations representing medical professionals and healthcare providers share this view.

The American College of Obstetricians and Gynecologists has declared acetaminophen - the primary component in Tylenol - is among limited choices for pregnant women to manage discomfort and elevated temperature, which can present major wellness concerns if ignored.

"In over twenty years of research on the use of paracetamol in pregnancy, zero credible investigations has conclusively proven that the usage of acetaminophen in any trimester of gestation leads to brain development issues in children," the group commented.

This legal action mentions current declarations from the Trump administration in claiming the drug is reportedly hazardous.

Last month, the former president caused concern from medical authorities when he advised pregnant women to "resist strongly" not to consume acetaminophen when unwell.

Federal regulators then published an announcement that doctors should think about restricting the usage of acetaminophen, while also stating that "a proven link" between the medication and autism in young ones has not been proven.

Health Secretary Robert F Kennedy Jr, who oversees the FDA, had pledged in spring to initiate "extensive scientific investigation" that would identify the origin of autism in a short period.

But experts cautioned that discovering a sole reason of autism spectrum disorder - believed by scientists to be the outcome of a complex mix of genetic and environmental factors - would be difficult.

Autism is a category of lifelong neurodivergence and condition that impacts how individuals experience and engage with the world, and is diagnosed using medical professional evaluations.

In his legal document, Paxton - a Trump ally who is seeking the Senate - asserts the manufacturer and Johnson & Johnson "willfully ignored and tried to quiet the evidence" around acetaminophen and autism spectrum disorder.

The lawsuit seeks to make the corporations "eliminate any commercial messaging" that claims Tylenol is reliable for expectant mothers.

The Texas lawsuit echoes the concerns of a assembly of parents of minors with autism spectrum disorder and ADHD who filed suit against the producers of acetaminophen in 2022.

The court rejected the legal action, declaring studies from the plaintiffs' authorities was not conclusive.

James Davis
James Davis

A passionate software engineer and tech writer, sharing knowledge on modern development practices and innovative solutions.